Overview

Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections

Status:
Completed

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

Summary

Our hypothesis is that large-dose, extended-interval vancomycin (30 mg/kg IV q24h) administration provides non-inferior clinical efficacy and microbiological efficacy to standard vancomycin (15 mg/kg IV q12h) administration for skin and soft tissue infections in an outpatient setting.

Phase:

N/A

Details

Lead Sponsor:

Fraser Health

Treatments:

Vancomycin